Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Tear Duct Blockage in Babies article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
The nasolacrimal duct usually canalises at eight months of fetal life but there is commonly a delay in this developmental process which can result in residual membrane tissue or stenosis at any level in the nasolacrimal system - from the canaliculi to the extreme end of the nasolacrimal duct underneath the inferior turbinate.
Congenital nasolacrimal duct obstruction (NLDO) is a common condition causing excessive tearing in the first year of life. The incidence of nasolacrimal duct obstruction in early childhood ranges from 5% to 20%.
Congenital nasolacrimal duct obstruction symptoms
Infants present with excessive tearing or mucoid discharge from the eyes due to blockage of the nasolacrimal duct system, which can result in maceration of the skin of the eyelids, sticky eyes, crusting of the eyelids and local infections, such as conjunctivitis.
Diagnosis is usually straightforward - but always consider:
- Congenital dacryocystocele (uncommon tense blueish swelling of the lacrimal sac) - acute inflammation occurs commonly and there may be an associated intranasal cyst. Refer to ophthalmology.
- Congenital conjunctivitis (ophthalmia neonatorum) or other conjunctivitis.
- Corneal abrasions.
- Congenital glaucoma - this is another important paediatric childhood condition that may present with epiphora. Photophobia, a difference in eye size (compare the diameter of the cornea of each eye with a simple desk-top clear ruler) and clouding of the cornea suggest congenital glaucoma which needs urgent ophthalmic assessment.
- Other congenital abnormality - eg, albinism or aniridia.
Fluorescein dye disappearance test may be helpful - a small drop of dye is instilled into both eyes and will normally disappear over five minutes if the duct is patent, and may subsequently be visible in the nostril using blue light.
However, this is usually a clinical diagnosis and using dye is often not necessary.
Congenital nasolacrimal duct obstruction often resolves without surgery. Treatment options are either conservative, including observation (or deferred probing), massage of the lacrimal sac, and antibiotics, or probing the nasolacrimal duct to open the membranous obstruction at the distal nasolacrimal duct. Probing may not be successful if the obstruction is due to a bony protrusion of the inferior turbinate into the nasolacrimal duct or when the duct is oedematous due to infection. Potential complications with probing include creation of a false passage and injury to the nasolacrimal duct, canaliculi and puncta, bleeding, laryngospasm, or aspiration. The effects and costs of immediate versus deferred probing are uncertain.
In most cases, simple massaging of the ducts may be enough because of the high rate of spontaneous resolution. Parents should be advised to apply gentle pressure with their finger over the common canaliculus, stroking downwards firmly to raise pressure in the lacrimal sac and encourage opening of the valve. They should perform ten strokes twice daily. They should also be advised to perform regular cleaning of any discharge from the eyelids.
Use topical antibiotics for any episodes of associated conjunctivitis (ie red conjunctiva as opposed to simple discharge).
In infants with nasolacrimal duct obstruction (NLDO) who are aged between 6 and 10 months, non-surgical management will resolve symptoms within six months in over half of cases.
Current guidelines are for children with persistent obstruction beyond 1 year of age to be referred for probing as a first-line interventional therapy. This is usually carried out under a brief general anaesthetic as a day case. However, the optimal timing for probing still remains controversial. Although there is still a high possibility of spontaneous resolution after 1 year of age, there is actually a reduction in success rates for probing with increasing age.
Surgical treatment is rarely considered before 6 months of age.
One study found that probing was successful in 75% of eyes overall. The procedure was less successful in eyes of children with bilateral NLDO compared with unilateral NLDO.
If symptoms persist after probing then the procedure can be repeated, usually with placement of a silicone stent to hold the passage open whilst it settles from the surgery. This remains in place for several months before removal, again usually with a brief general anaesthetic. Occasionally a dacryocystorhinostomy (DCR) procedure is required.
Conjunctivitis is the most common complication. This can be managed with simple topical antibiotics. The baby may also be born with - or develop - a dacryocystocele (mucocele) whereby fluid (eg, amniotic fluid) enters the sac and is retained by the non-patent duct. This may lead to acute dacryocystitis.
The risks of probing include:
- Failure - the risks of this increase exponentially with age and number of probings.
- Creation of a false passage.
- Bleeding (rare).
Further reading and references
Petris C, Liu D; Probing for congenital nasolacrimal duct obstruction. Cochrane Database Syst Rev. 2017 Jul 127:CD011109. doi: 10.1002/14651858.CD011109.pub2.
Moore DB, Tomkins O, Ben-Zion I; A review of primary congenital glaucoma in the developing world. Surv Ophthalmol. 2013 May-Jun58(3):278-85. doi: 10.1016/j.survophthal.2012.11.003. Epub 2013 Mar 5.
Vagge A, Ferro Desideri L, Nucci P, et al; Congenital Nasolacrimal Duct Obstruction (CNLDO): A Review. Diseases. 2018 Oct 226(4). pii: diseases6040096. doi: 10.3390/diseases6040096.
Avram E; Insights in the treatment of congenital nasolacrimal duct obstruction. Rom J Ophthalmol. 2017 Apr-Jun61(2):101-106. doi: 10.22336/rjo.2017.19.
Nasolacrimal duct obstruction (nasolacrimal drainage dysfunction); College of Optometrists, March 2016
Resolution of congenital nasolacrimal duct obstruction with nonsurgical management; Arch Ophthalmol. 2012 Jun130(6):730-4. doi: 10.1001/archophthalmol.2012.454.
Takahashi Y, Kakizaki H, Chan WO, et al; Management of congenital nasolacrimal duct obstruction. Acta Ophthalmol. 2009 Jul 21.
Miller AM, Chandler DL, Repka MX, et al; Office probing for treatment of nasolacrimal duct obstruction in infants. J AAPOS. 2014 Feb18(1):26-30. doi: 10.1016/j.jaapos.2013.10.016.
Memon MN, Siddiqui SN, Arshad M, et al; Nasolacrimal duct obstruction in children: outcome of primary intubation. J Pak Med Assoc. 2012 Dec62(12):1329-32.